Main Line

Following the Recent Label Expansion, Biohaven’s Nurtec ODT Has Come Out Strong in the Migraine Prevention Market, According to Spherix Global Insights

EXTON, Pa., Sept. 9, 2021 /PRNewswire/ — In May 2021, the FDA approved the label expansion of Biohaven’s Nurtec ODT for the preventive treatment of episodic migraine, making the gepant the first and ...
The Times Herald

Biohaven’s Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly’s Emgality, According to Spherix ...

EXTON, Pa., Sept. 23, 2021 /PRNewswire/ — Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli Lilly announced initiation of a ...
Nasdaq

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...
Yahoo Finance

Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

Biohaven Pharmaceutical BHVN incurred loss of $3.23 per share in second-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $2.77 as well as the year-ago loss of $3.08. Adjusted loss, ...
Mena FN

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update'

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...
Nasdaq

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

Biohaven Pharmaceutical BHVN announced that the FDA has accepted its supplemental new drug application (sNDA) for its migraine drug Nurtec ODT (rimegepant). The sNDA is seeking a label expansion of ...